Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease
- 30 January 2017
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 37 (9) , 1304-1313
Abstract
Background & Aims: We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment‐naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients with pre‐defined NS5A resistance‐associated substitutions.Methods: This phase II, open‐label, single‐arm, multicentre study included patients aged ≥18 years with advanced fibrosis or compensated cirrhosis (METAVIR F3/4). Patients with NS5A‐Y93H or L31M/V resistance‐associated substitutions at screening were excluded. Simeprevir (150 mg)+daclatasvir (60 mg) once daily was administered for 12 or 24 weeks; treatment could be extended to 24 weeks prior to or at the Week 12 visit. Primary efficacy endpoint was sustained virological response 12 weeks after the end of treatment.Results: A total of 106 patients were treated; 27% patients were aged >65 years, 39% had cirrhosis, 53% had estimated glomerular filtration rate 30‐89 mL/min, 14% had diabetes, and 38% had arterial hypertension. Overall, 42/106 received 12 weeks of treatment and 64/106 received 24 weeks of treatment. Ninety‐seven (92%) patients achieved a sustained virological response 12 weeks after the end of treatment. The reasons for failure were viral breakthrough (n=7) at weeks 4‐16, early treatment discontinuation (n=1) and viral relapse (n=1). Seventy‐four (70%) patients had ≥1 adverse event during treatment, including six (6%) patients with ≥1 serious adverse event. Three (3%) patients discontinued treatment owing to adverse events.Conclusions: Simeprevir+daclatasvir demonstrated strong antiviral activity and was well‐tolerated in patients with hepatitis C virus genotype 1b infection, advanced liver disease and a high prevalence of comorbidities. However, viral breakthrough occurred in seven patients, making this regimen unsatisfactory.Keywords
Funding Information
- Janssen Pharmaceutica
This publication has 22 references indexed in Scilit:
- Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionJournal of Hepatology, 2016
- Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapyAlimentary Pharmacology & Therapeutics, 2016
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Mechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsViruses, 2015
- Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected PatientsPLOS ONE, 2015
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialThe Lancet HIV, 2015
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Management of patients with hepatitis C infection and renal diseaseWorld Journal of Hepatology, 2014
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- 1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977Journal of Hepatology, 2012